SUTENT More Than Doubled Median Progression-Free Survival (PFS) vs IFNα

• 11 months vs 5 months with IFNα (95% CI: 9.8, 11.7 and 3.8, 5.5, respectively; P<.000001)

SUTENT Achieved More Than 2 Years' Median
Overall Survival (OS)

• 26.4 months vs 21.8 months with IFNα (Unstratified: HR=0.82; 95% CI: 0.673, 1.001; P=.051 [log-rank])¹

Patients on SUTENT Demonstrated a Nearly 5-Fold Higher Response vs IFNα

• 28% vs 5% with IFNα (95% CI: 23.0, 32.3 and 3.3, 8.1, respectively; P<.001) in the first analysis
• 39% vs 8% with IFNα (95% CI: 34.0, 44.3 and 5.7, 11.8, respectively; P<.000001) in the second analysis¹
  • Response was defined by RECIST and assessed by blinded core review at 2
    different time points¹

RECIST defines PR as a ≥30% decrease from baseline in the sum of the longest diameter of target lesions; SD as insufficient tumor shrinkage for PR but <20% increase for PD in the smallest sum of the longest diameter of target lesions from baseline since the treatment started; PD as a ≥20% increase in the sum of the longest diameter of target lesions from the smallest sum of the longest diameter of target lesions recorded since the treatment started, or the appearance of 1 or more new lesions.²

Time to Tumor Response

• Time to tumor response may vary:
  • Responses for SUTENT occurred as early as 3.7 weeks and as late as 48.7 weeks
  • Responses for IFNα occurred as early as 3.9 weeks and as late as 48.3 weeks
• Among patients who responded to SUTENT, 94% did so within the first 24 weeks of
  therapy¹

*Patients underwent scans of their primary tumor at baseline, at least once per cycle thereafter, and upon completion of treatment. Results are from a post hoc subgroup analysis. As with any retrospective analysis, there may be interpretive limitations.